Urine tenofovir point-of-care test to identify patients in need of ART adherence support
Urine tenofovir point-of-care test to identify patients in need of ART adherence support
批准号:
10462600
负责人:
Monica Gandhi
金额:
$33.89万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-07-07 至 2025-06-30
关键词:
AdherenceAftercareAgreementAnti-Retroviral AgentsAntibodiesBiological AssayBloodCaliforniaCaringClient satisfactionClinicClinic VisitsClinicalCounselingCross-Sectional StudiesDevelopmentDiphosphatesDrug resistanceEnrollmentFailureFeedbackGrantGuidelinesHIVHIV-1HairHealthHealth PersonnelImmunoassayImmunologicsIndividualInterventionInterviewLaboratoriesLamivudineLength of StayMeasuresModernizationMonitorOutcomeParticipantPatient RecruitmentsPatient Self-ReportPatientsPerceptionPharmaceutical PreparationsPharmacy facilityPlasmaPrimary Health CareProcessProviderPsychological reinforcementQuestionnairesRampRandomized Controlled TrialsRapid diagnosticsRegimenResistanceResource-limited settingRiskSamplingSan FranciscoScientistService delivery modelServicesSouth AfricaSouth AfricanSpecificitySpottingsSupervisionSurveysTechnologyTenofovirTestingTimeTreatment FailureUnderrepresented PopulationsUniversitiesUrineVertebral columnViral Load resultViral load measurementVisitacceptability and feasibilityantiretroviral therapyarmbasebehavioral adherencecare systemscompliance behaviorcostdesignfollow-uphigh riskimprovedimproved outcomeinstrumentationintervention participantsnovelpoint of carepoint of care testingpreventprimary outcomerandomized controlled studyrapid testsecondary outcomeside effectstandard of caresuccesssupport toolstherapy adherencetooltransmission processtreatment adherencetreatment armviral resistance
中文摘要
项目总结
需要足够的联合抗逆转录病毒疗法(ART)来抑制HIV病毒载量
艾滋病毒携带者,这对个人层面的利益和防止艾滋病毒继续传播是必不可少的
艾滋病毒的传播。虽然新的ART方案耐受性更好,但副作用更少,风险更低
尽管与旧方案相比耐药,但治疗成功仍取决于患者的依从性。
目前确定遵守不充分的方法要么是主观的,要么是不敏感的,而客观的
头发、干血斑点或血浆中的治疗暴露(药物水平)标记物需要昂贵
工具,因此不可伸缩。因为治疗的最终目的是达到HIV病毒载量
除了抑制,艾滋病毒病毒载量检测的使用正在世界范围内推广。由于它仍然是一项昂贵的测试,它是
通常不经常进行,因此发现治疗失败的时间较晚,导致错失了治疗机会
提高遵从性。临床上客观评估抗逆转录病毒治疗依从性的低成本护理点(POC)分析
在资源受限设置(RLS)中的访问可以:1)提供有关最近遵守的即时信息
随后可提供适当的遵从性支持;2)允许更频繁地评估遵从性
并在病毒学失败之前加强适当的坚持行为;3)区分患者
由于耐药者对病毒的依从性差而导致病毒学失败。最后,随着目前推出的
替诺福韦、拉米夫定和多洛替格韦(TLD)在RLS中,失败率预计很低,耐药性很少,
有必要制定一项监测策略,主要侧重于识别依从性不足的患者。
最近,加州大学旧金山分校的头发分析实验室和雅培™快速
诊断公司已经开发出一种基于尿液的替诺福韦(TFV)免疫分析方法。这种基于抗体的检测方法可以检测到
TFV在尿液中的存在准确,易于操作,而且成本低(每次检测2美元),而且
Of-care(POC),允许立即向患者和提供者提供依从性反馈。
因此,我们将进行一项旨在以下目的的研究:1)考察尿基替诺福韦的能力
一项横断面研究中检测病毒学故障的快速检测(UTRA),以及UTRA与
自我报告的依从性和长期接触TFV的干血斑(120名患者);
定性评估UTRA在患者(25人)和医护人员(5人)中的可接受性;3)进行试点
在依从性挑战患者中进行的随机对照研究,以考察其有效性、可行性和
与标准护理咨询相比,UTRA支持的依从性咨询对影响的可接受性
艾滋病毒病毒载量的长期结果(每组100名患者)。预计的总体影响是,到研究结束时,
我们希望已经在一个资源中验证了这个基于尿液的新型实时治疗依从性监测工具-
有限的设置,并通知较大的试验以触发立即依从性支持和更昂贵的配给
实验室检测,使用实用的POC检测,以改善全球病毒学的长期结果。
英文摘要
PROJECT SUMMARY
Adequate adherence to combination antiretroviral therapy (ART) is required to suppress HIV viral loads among
individuals living with HIV, which is essential both for individual-level benefits and to prevent the onward
transmission of HIV. While newer ART regimens are better tolerated, have fewer side effects and a lower risk of
drug resistance than older regimens, treatment success nevertheless remains dependent on patient adherence.
Current approaches to identify inadequate adherence are either subjective or insensitive, whereas objective
markers of treatment exposure (drug levels) in hair, dried blood spots or plasma require expensive
instrumentation and are therefore not scalable. As the ultimate aim of treatment is to achieve HIV viral load
suppression, use of HIV viral load testing is being expanded worldwide. As it remains an expensive test, it is
often performed infrequently and therefore treatment failure is detected late, resulting in missed opportunities to
improve adherence. A low-cost point-of-care (POC) assay to assess adherence to ART, objectively at clinic
visits, in resource limited settings (RLS), could: 1) Provide immediate information on recent adherence which
can then be followed with appropriate adherence support; 2) Allow for more frequent assessment of adherence
and reinforcement of appropriate adherence behavior before virologic failure occurs; 3) Differentiate patients
with virological failure due to poor adherence from those with drug resistance. Finally, with the current roll-out of
tenofovir, lamivudine and dolutegravir (TLD) in RLS, failure rates are expected to be low and resistance rare,
necessitating a monitoring strategy primarily focused on identifying patients with inadequate adherence.
Recently the University of California, San Francisco (UCSF) Hair Analytical Laboratory and Abbott™ Rapid
Diagnostics has developed a urine-based immunoassay for tenofovir (TFV). This antibody-based assay detects
the presence of TFV in urine accurately, is easy-to-perform, and is both low-cost (< $2 dollars per test) and point-
of-care (POC), which allows for immediate adherence feedback to both patient and provider.
We will therefore conduct a study with the following aims: 1) Investigate the ability of the urine-based tenofovir
rapid assay (UTRA) to detect virologic failure in a cross-sectional study, along with the association of UTRA with
self-reported adherence and long term TFV exposure as measured in dried blood spots (120 patients); 2)
Qualitatively assess the acceptability of UTRA in patients (25) and health care workers (5); 3) Perform a pilot
randomized controlled study among adherence-challenged patients to investigate the usefulness, feasibility and
acceptability of UTRA-supported adherence counseling, compared to standard of care counseling, to impact
long-term HIV viral load outcomes (100 patients in each arm). The envisaged overall impact is that by study end,
we hope to have validated this novel real-time urine-based treatment adherence monitoring tool, in a resource-
limited setting, and inform a larger trial to trigger immediate adherence support and ration more expensive
laboratory testing, using the practical POC test, to improve long-term virologic outcomes worldwide.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Unraveling the intersection of substance use, inflammation, and HIV via hair levels
-
批准号:10761023
-
项目类别:
-
资助金额:$77.47万
-
财政年份:2023
-
负责人:Monica Gandhi
-
依托单位:
Evaluation of the Impact of HIV Status on the Immune Response to mRNA COVID-19 Vaccines
-
批准号:10481408
-
项目类别:
-
资助金额:$20.19万
-
财政年份:2022
-
负责人:Monica Gandhi
-
依托单位:
Evaluation of the Impact of HIV Status on the Immune Response to mRNA COVID-19 Vaccines
-
批准号:10581700
-
项目类别:
-
资助金额:$24.23万
-
财政年份:2022
-
负责人:Monica Gandhi
-
依托单位:
The HIV Nexus Scholars Program: A Research Education Program for Early-Stage Investigators Working at the Intersection of Biomedical, Social/Behavioral, and Clinical Science
-
批准号:10313585
-
项目类别:
-
资助金额:$35.1万
-
财政年份:2021
-
负责人:Monica Gandhi
-
依托单位:
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic
-
批准号:10169797
-
项目类别:
-
资助金额:$70.98万
-
财政年份:2020
-
负责人:Monica Gandhi
-
依托单位:
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic
-
批准号:10462510
-
项目类别:
-
资助金额:$80.26万
-
财政年份:2020
-
负责人:Monica Gandhi
-
依托单位:
Urine tenofovir point-of-care test to identify patients in need of ART adherence support
-
批准号:10211122
-
项目类别:
-
资助金额:$34.39万
-
财政年份:2020
-
负责人:Monica Gandhi
-
依托单位:
Objective measures of adherence for later-stage ART failure in resource limited settings
-
批准号:10012880
-
项目类别:
-
资助金额:$8.05万
-
财政年份:2020
-
负责人:Monica Gandhi
-
依托单位:
Urine tenofovir point-of-care test to identify patients in need of ART adherence support
-
批准号:9983237
-
项目类别:
-
资助金额:$34.35万
-
财政年份:2020
-
负责人:Monica Gandhi
-
依托单位:
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic
-
批准号:10669735
-
项目类别:
-
资助金额:$79.85万
-
财政年份:2020
-
负责人:Monica Gandhi
-
依托单位:
Evaluation of the Interplay between HIV and COVID-19 in a large urban safety-net HIV clinic
-
批准号:10224038
-
项目类别:
-
资助金额:$79.94万
-
财政年份:2020
-
负责人:Monica Gandhi
-
依托单位:
Urine tenofovir point-of-care test to identify patients in need of ART adherence support
-
批准号:10831377
-
项目类别:
-
资助金额:$33.19万
-
财政年份:2020
-
负责人:Monica Gandhi
-
依托单位:
Point-of-care Urine Monitoring of Adherence (PUMA): Testing a Real-Time Urine Assay of Tenofovir in PrEP
-
批准号:10231188
-
项目类别:
-
资助金额:$67.64万
-
财政年份:2018
-
负责人:Monica Gandhi
-
依托单位:
Point-of-care Urine Monitoring of Adherence (PUMA): Testing a Real-Time Urine Assay of Tenofovir in PrEP
-
批准号:9789815
-
项目类别:
-
资助金额:$69.49万
-
财政年份:2018
-
负责人:Monica Gandhi
-
依托单位:
Point-of-care Urine Monitoring of Adherence (PUMA): Testing a Real-Time Urine Assay of Tenofovir in PrEP
-
批准号:10475042
-
项目类别:
-
资助金额:$76.66万
-
财政年份:2018
-
负责人:Monica Gandhi
-
依托单位:
Novel methods of pharmacologic monitoring for multidrug resistant tuberculosis treatment in the setting of HIV infection
-
批准号:9065307
-
项目类别:
-
资助金额:$76.54万
-
财政年份:2016
-
负责人:Monica Gandhi
-
依托单位:
Hair measures to assess adherence and explain outcomes in an HIV clinical trial
-
批准号:8730255
-
项目类别:
-
资助金额:$18.9万
-
财政年份:2014
-
负责人:Monica Gandhi
-
依托单位:
Recent Advances in HIV Research
-
批准号:10696853
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2012
-
负责人:Monica Gandhi
-
依托单位:
Recent Advances in AIDS and HIV Research
-
批准号:9761957
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2012
-
负责人:Monica Gandhi
-
依托单位:
Recent Advances in AIDS and HIV Research
-
批准号:10225332
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2012
-
负责人:Monica Gandhi
-
依托单位:
海外基金